wellrank.ai
Ovidrel logo

Ovidrel

First cited by AI Jun 13, 2026

Surfaced organically in AI answers about trt and men's health. Not yet profiled.

AI Visibility

Visibility trend

TRT and men's health, daily share of AI answers mentioning Ovidrel, through Jun 13, 2026.

8.3%

Avg position when mentioned: 9.0

By engine

Where Ovidrel is strong, and where it is invisible.

  • ChatGPT
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 0 positive mentions
  • 1 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Ovidrel

ChatGPTJun 13, 2026, 11:03 UTC
What testosterone level is low enough to need treatment?

Short answer: most guidelines use a total testosterone cutoff of about 300 ng/dL (≈10.4 nmol/L). Treatment is usually considered only if you have consistent low measurements plus symptoms of testosterone deficiency. Details and what that means for you Typical adult male total testosterone reference is roughly 300–1,000 ng/dL (10.4–34.7 nmol/L), though lab ranges vary. The Endocrine Society and American Urology Association commonly use a threshold of ~300 ng/dL. If total testosterone is below ~300 ng/dL on at least two morning (7–10 a.m.) measurements and you have symptoms (low libido, erectile problems, low energy/mood, loss of muscle mass, increased body fat, anemia, decreased bone density), treatment may be appropriate. Very low values (for example <200 ng/dL) are much more likely to cause symptoms and to prompt treatment or urgent evaluation. Important caveats Measure testosterone in the morning, while fasting if possible, and repeat the test because illness, stress, some meds, and acute medical problems can transiently lower levels. If total testosterone is borderline (250–350 ng/dL) or if you have conditions that change SHBG (obesity, diabetes, liver disease, thyroid disease), free testosterone or calculated bioavailable testosterone should be checked — labs report different reference ranges, so compare to your lab’s normal values. You also need further testing to find the cause: LH/FSH (to distinguish primary vs secondary hypogonadism), prolactin, and sometimes iron studies, sleep apnea screen, and metabolic testing. When NOT to give therapy and other concerns Don’t start exogenous testosterone if you have suspected or active breast or prostate cancer. Other contraindications/precautions include very high hematocrit, uncontrolled heart failure, and some recent cardiovascular events — these need individualized discussion with a clinician. Exogenous testosterone suppresses sperm production and can cause infertility. If you want to preserve or build fertility, alternatives include clomiphene citrate (commonly used off‑label) or hCG — discuss with a specialist. Common treatment options (examples and why) Topical gels: AndroGel, Testim — steady daily dosing, easy to use, but risk of transfer to others. Transdermal patch: Androderm — steady delivery, once-daily patch. Intramuscular injections: testosterone cypionate/enantate (often dispensed as Depo-Testosterone or generic testosterone cypionate) — less expensive, given every 1–3 weeks; can cause peaks and troughs. Long‑acting injections (testosterone undecanoate: Aveed/Nebido) provide more stable levels but require specific administration. Nasal: Natesto — multiple daily doses, lower systemic exposure between doses for some people. Fertility-preserving therapies: clomiphene citrate (Clomid, off‑label in men) or hCG (Ovidrel or prescribed hCG products) to raise endogenous testosterone without suppressing spermatogenesis as much. Monitoring if you start therapy Regular follow‑up with serum testosterone (to target mid‑normal range), hematocrit (risk of polycythemia), PSA, lipids, liver tests as indicated, and assessment of symptoms. Next step See your primary care doctor, urologist, or endocrinologist. Ask for a morning total testosterone test (and repeat it if low), plus LH/FSH and prolactin if the result is low. If you want, tell me your lab number(s) and symptoms and I can help interpret them and outline likely next steps.

Mentioned in position 9 of 9

Read full answer with sources →

Public AI visibility history

Daily rank of Ovidrel on our buyer intent questions, per category. A dash means the engines did not cite Ovidrel at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
TRT and men's health#35

TL;DR

Ovidrel is a brand name for choriogonadotropin alfa, a recombinant human chorionic gonadotropin (r-hCG) injection manufactured by EMD Serono and used primarily to trigger ovulation in fertility treatments. While its primary indication is female infertility, it surfaces in AI answers related to TRT and men's health because hCG is sometimes used off-label in men to stimulate testosterone production or preserve fertility during testosterone therapy. According to WellRank's latest index, Ovidrel ranks tenth in AI-generated answers about TRT and men's health, carrying 8% visibility with a predominantly neutral tone in AI citations.

Company Overview

Ovidrel is a prescription fertility medication marketed by EMD Serono, the biopharmaceutical arm of Merck KGaA, a German multinational. The product is a recombinant form of human chorionic gonadotropin delivered via prefilled subcutaneous injection. EMD Serono operates on a specialty-pharmaceutical business model, distributing Ovidrel through specialty pharmacies and fertility clinics rather than general retail channels.

Product Features

  • Recombinant human chorionic gonadotropin (r-hCG) as the active ingredient, produced through recombinant DNA technology
  • Single-use prefilled 250 mcg subcutaneous injection pen for ease of self-administration
  • FDA-approved trigger shot for final follicular maturation and early luteinization in assisted reproductive technology cycles
  • Used off-label in men to support endogenous testosterone production and testicular function during or after testosterone therapy
  • Precise dosing consistency compared to urinary-derived hCG products

Target Market

Ovidrel is FDA-approved for women undergoing assisted reproductive technology or ovulation induction, making fertility clinics and reproductive endocrinologists its primary prescribers. It is also used off-label by urologists and men's health specialists for men experiencing hypogonadotropic hypogonadism or seeking to maintain fertility while on testosterone replacement therapy. The product is available in the United States and other markets where EMD Serono holds regulatory approval.

Buyer Personas

  • A woman in her thirties undergoing IVF at a fertility clinic who needs a reliable, self-administered trigger shot to time egg retrieval precisely.
  • A man on testosterone replacement therapy whose physician has added hCG to preserve testicular size and fertility.
  • A younger man with hypogonadotropic hypogonadism prescribed hCG to stimulate endogenous testosterone and sperm production.
  • A reproductive endocrinologist or urologist sourcing a consistent, recombinant hCG product for their patient protocols.

Funding & Performance

Ovidrel is a branded prescription product of EMD Serono, itself a subsidiary of publicly traded Merck KGaA (Frankfurt: MRK). Specific revenue figures attributable to Ovidrel alone are not publicly disclosed as a standalone line item.

Recent Developments

EMD Serono has maintained Ovidrel as a core fertility portfolio product for many years. Growing clinical interest in hCG as an adjunct to male testosterone therapy has expanded the contexts in which Ovidrel appears in medical literature and AI-generated health answers, which aligns with its appearance in WellRank's TRT and men's health category. No major formulation changes or new indications have been widely announced in recent public communications.

Competitive Landscape

In the TRT and men's health AI-answer space where WellRank tracks Ovidrel, it surfaces alongside brands including Testim, Nebido, Natesto, Depo-Testosterone, Clomid, Aveed, Androderm, and AndroGel. Most of those competitors are direct testosterone-delivery products, whereas Ovidrel occupies a narrower niche as an hCG-based adjunct or alternative, meaning its competitive relevance in this category is largely defined by off-label male use rather than its primary fertility indication.

Ovidrel vs the brands AI recommends alongside it

The real competitive set in TRT and men's health: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Ovidrel logo
OvidrelThis brand
#35
8.3%
AndroGel logo
AndroGel

1 shared answers

#21
8.3%
Androderm logo
Androderm

1 shared answers

#24
8.3%
Aveed logo
Aveed

1 shared answers

#26
8.3%
Clomid logo
Clomid

1 shared answers

#30
8.3%

Email me when overtakes Ovidrel

One email the day the ranks flip. Nothing else.

User Sentiment

Based on WellRank's current corpus, Ovidrel has appeared in one AI-generated mention in the TRT and men's health category, and that mention is neutral in tone, with no positive or cautionary framing recorded. This limited signal suggests AI engines reference Ovidrel factually and contextually rather than as a recommended or criticized option in men's health discussions. Broader patient sentiment in fertility communities tends to be practical and procedure-focused, as the product is typically one step in a larger clinical protocol.

Pricing

Ovidrel is a specialty prescription product and its retail and specialty-pharmacy pricing varies by insurance coverage, patient assistance programs, and dispensing channel. Exact out-of-pocket figures are not published in a stable, widely verifiable form, so pricing should be confirmed directly with a specialty pharmacy or through EMD Serono's patient-support resources.

Sources cited around Ovidrel

The sites engines cite in answers mentioning this brand. Win these, win the answer.

    Track Ovidrel weekly

    One email a week: rank moves, new competitors, and the answers that changed. No noise.

    Work at Ovidrel? Get your AI Visibility Audit.

    See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.